Noxopharm launches NOXCOVID-1 clinical trial of Veyonda across Europe
Noxopharm, an Australian clinical-stage pharma company, has started the phase 1 NOXCOVID-1 clinical trial for Veyonda in Europe to evaluate the anti-cancer drug candidate as a potential treatment for cytokine storm and septic shock in COVID-19 patients. With a capability to inhibit cGAS-STING signalling, Veyonda can potentially block the start of the cytokine storm which […]